（来源：头豹）

同源康医药三款创新药研究成果获2025年ESMO大会收录

同源康医药（股票代码：02410.HK）今日宣布，公司自主研发的三款创新药物——CDK2/4抑制剂TY-00540、CDK7抑制剂TY-2699a及CDK4/6抑制剂TY-302的I期临床试验结果，正式获2025年欧洲肿瘤内科学会（ESMO）大会以壁报形式收录。相关详细数据将于会议期间展示，并同步发表于ESMO官方期刊《Annals of Oncology》。作为全球肿瘤学领域最具影响力的学术会议之一，此次收录标志着国际学术界对这三款药物早期临床价值的认可。

三款创新药核心亮点速览

CDK2/4抑制剂TY-00540展现广谱抗肿瘤潜力

作为同源康医药自主研发的CDK2/4抑制剂，TY-00540对CDK2/CycA2、CDK2/CycE1等核心靶点表现出强效抑制作用，同时对CDK4/CycD1、CDK6/CycD3等关联靶点亦具备抑制活性。临床前和临床研究显示，该药物在乳腺癌（包括哌柏西利耐药模型）、卵巢癌等多种实体瘤中均展现出显著抑制效果及良好安全性。本次收录数据来自I期多中心开放临床试验（NCT06246071），目前Ib/II期临床研究正在推进中。

潜在"同类最佳"CDK7抑制剂TY-2699a彰显治疗优势

TY-2699a是同源康医药开发的新一代CDK7抑制剂，在25种CDK家族激酶筛选中展现出对CDK7的高度选择性。临床前研究证实，该药物可在正常细胞不敏感的剂量下精准抑制癌细胞生长。初步临床数据显示，TY-2699a在同类剂量水平下兼具优异安全性和初步疗效。本次收录数据源自I期多中心单药递增临床试验（NCT05866692），目前针对三阴性乳腺癌（TNBC）的单药扩展试验正在进行。

差异化CDK4/6抑制剂TY-302优化治疗体验

TY-302是同源康医药研发的差异化CDK4/6抑制剂，临床前研究显示其具有更低的胃肠道副作用和更可控的血液学毒性特征。I期临床数据显示，该药物与托瑞米芬联用治疗HR+/HER2-晚期乳腺癌末线患者时，展现出显著疗效和良好安全性。本次收录数据来自I期多中心联合用药临床试验（NCT04433494），后续临床研究持续开展中。

关于ESMO

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤学专业学术组织。2025年ESMO年会将于10月17-21日在德国柏林举行，预计吸引全球逾3万名肿瘤领域专家学者参与。此次三款药物研究获大会收录，体现了国际学术界对同源康医药创新研发方向的高度认可。

关于同源康医药

同源康医药是一家专注于肿瘤创新药物研发的生物医药公司，致力于通过自主研发与全球合作，为患者提供突破性治疗方案。目前公司多个创新项目处于临床或临床前开发阶段，已形成丰富的产品管线布局。

此次ESMO大会收录的三项临床成果，将为三款药物的后续开发奠定重要基础。同源康医药期待通过国际学术交流平台，与全球专家深入探讨优化研发策略，加速创新成果转化，为全球肿瘤患者带来更多治疗选择。

TYK medicines’ Three Innovative Drug Candidates Selected for Inclusion at the 2025 ESMO Congress

TYK medicines (Stock Code: 02410.HK) announced today that three of its independently developed innovative drug candidates—CDK2/4 inhibitor TY-00540, CDK7 inhibitor TY-2699a, and CDK4/6 inhibitor TY-302—have been officially accepted for poster presentation at the 2025 European Society for Medical Oncology (ESMO) Congress. Detailed data will be showcased during the event and simultaneously published in ‘Annals of Oncology’, the official journal of ESMO. As one of the most influential academic conferences in the field of oncology globally, this inclusion signifies international recognition of the early clinical value of these three drug candidates.

Highlights of the Three Innovative Drugs

CDK2/4 Inhibitor TY-00540: Broad-Spectrum Anti-Tumor Potential

TY-00540, developed by TYK medicines, is a CDK2/4 inhibitor that shows potent activity against key targets such as CDK2/CycA2 and CDK2/CycE1, while also demonstrating inhibitory activity on related targets including CDK4/CycD1 and CDK6/CycD3. Preclinical and clinical studies have shown that TY-00540 exhibits significant tumor suppression across multiple solid tumors, including breast cancer (even in palbociclib-resistant models) and ovarian cancer, with a favorable safety profile. The data accepted at ESMO come from a Phase I multicenter open-label trial (NCT06246071), with Phase Ib/II trials currently underway.

Potential Best-in-Class CDK7 Inhibitor TY-2699a: Therapeutic Advantages Emerging

TY-2699a is a next-generation CDK7 inhibitor developed by TYK medicines. Among a panel of 25 CDK family kinases, it showed exceptional selectivity for CDK7. Preclinical studies demonstrated that TY-2699a can precisely inhibit cancer cell growth at doses that are non-toxic to normal cells. Early clinical data indicate strong safety and promising preliminary efficacy at comparable dosage levels. The data included at ESMO originate from a Phase I multicenter dose-escalation monotherapy study (NCT05866692), with an ongoing monotherapy expansion trial focused on triple-negative breast cancer (TNBC).

Differentiated CDK4/6 Inhibitor TY-302: Optimized Treatment Experienc

TY-302 is a differentiated CDK4/6 inhibitor developed by TYK medicines. Preclinical studies suggest it causes fewer gastrointestinal side effects and offers more manageable hematologic toxicity. Phase I clinical data show that, when combined with toremifene, TY-302 delivers strong efficacy and good safety in patients with HR+/HER2− advanced breast cancer who have exhausted other treatment options. The ESMO-included data Stem from a Phase I multicenter combination therapy trial (NCT04433494), with further clinical development ongoing.

About ESMO

Founded in 1975, the European Society for Medical Oncology (ESMO) is one of the world's leading Professional organizations for medical oncology. The 2025 ESMO Annual Congress will be held in Berlin, Germany, from October 17–21 and is expected to draw over 30,000 oncology experts and researchers from around the globe. The inclusion of TYK medicines’ three drug candidates in this prestigious conference underscores the international academic community’s recognition of the company’s innovation and research direction.

About TYK medicines

TYK medicines is a biotech company focused on the development of innovative cancer therapies. Through independent R&D and global collaborations, the company aims to deliver groundbreaking treatment solutions to patients. Multiple projects are currently in preclinical or clinical stages, with a robust and Diversified pipeline.

The three clinical studies accepted at this year’s ESMO Congress provide a solid foundation for further development of these therapies. TYK medicines looks forward to using the international academic platform to engage deeply with global experts, refine R&D strategies, accelerate innovation, and expand treatment options for cancer patients worldwide.